FibroGen (FGEN) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1-year price objectives for FibroGen's stock. Their FGEN share price forecasts range from $2.00 to $35.00. On average, they expect the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 2,872.6% from the stock's current price.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.

FibroGen's stock was trading at $16.02 at the beginning of the year. Since then, FGEN shares have decreased by 95.4% and is now trading at $0.7401.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FGEN earnings forecast.

FibroGen, Inc. (NASDAQ:FGEN) released its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.07. The biopharmaceutical company had revenue of $44.32 million for the quarter, compared to analyst estimates of $34.17 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 246.75%.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $0.74.

FibroGen (NASDAQ:FGEN) has a market capitalization of $72.69 million and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

The company employs 592 workers across the globe.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.